ConductScience.org, home

Paper40539780

Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.

Xu J-Z and 13 others. J Virol, 2025. Cited by 8 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis. Papers, record 40539780. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40539780

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.
PubMed
Journal
J Virol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Systematic Review, Meta-Analysis
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.27, provisional
iCite
Revised in PubMed
2026-03-24
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xu J-ZJin-Zhouhttps://orcid.org/0000-0002-2696-2238
2Sun J-XJian-Xuan
3Liu C-QChen-Qian
4Pan R-YRuo-Yan
5Zeng NNa
6Zhang S-HSi-Han
7An YYe
8Xu M-YMeng-Yao
9Zhong X-YXing-Yu
10Ma S-YSi-Yang
11He H-DHao-Dong
12Hu JJia
13Wang S-GShao-Ganghttps://orcid.org/0000-0002-3206-1495
14Xia Q-DQi-Donghttps://orcid.org/0000-0002-2278-1122

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Oncolytic VirotherapyMajor topic
Oncolytic VirusesMajor topic
Humans
Treatment Outcome

Source PubMed

References113

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,298,410Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.J Clin Oncol2016https://conductscience.org/library/papers/27298410PubMed
235,116,288The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.Transl Cancer Res2021https://conductscience.org/library/papers/35116288PubMed
339,820,126Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nat Cancer2025https://conductscience.org/library/papers/39820126PubMed
436,651,961Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/36651961PubMed
532,052,079Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.Cancer Immunol Immunother2020https://conductscience.org/library/papers/32052079PubMed
634,464,163Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.J Clin Oncol2021https://conductscience.org/library/papers/34464163PubMed
739,826,543Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients.Cell2025https://conductscience.org/library/papers/39826543PubMed
839,414,325First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments.J Immunother Cancer2024https://conductscience.org/library/papers/39414325PubMed
937,292,376A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.Front Pediatr2023https://conductscience.org/library/papers/37292376PubMed
1033,875,611Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.J Immunother Cancer2021https://conductscience.org/library/papers/33875611PubMed
1136,631,681Therapy with oncolytic viruses: progress and challenges.Nat Rev Clin Oncol2023https://conductscience.org/library/papers/36631681PubMed
1228,529,585Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial.Oncol Lett2017https://conductscience.org/library/papers/28529585PubMed
1319,287,305Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.Anticancer Drugs2009https://conductscience.org/library/papers/19287305PubMed
1433,219,014A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.Clin Cancer Res2021https://conductscience.org/library/papers/33219014PubMed
1536,402,738The emerging field of oncolytic virus-based cancer immunotherapy.Trends Cancer2023https://conductscience.org/library/papers/36402738PubMed
1639,915,002Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.J Immunother Cancer2025https://conductscience.org/library/papers/39915002PubMed
1737,060,176Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.Mol Ther2023https://conductscience.org/library/papers/37060176PubMed
1810,932,224a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.Nat Med2000https://conductscience.org/library/papers/10932224PubMed
1931,563,865How to perform a meta-analysis with R: a practical tutorial.Evid Based Ment Health2019https://conductscience.org/library/papers/31563865PubMed
2029,653,857A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.Clin Colorectal Cancer2018https://conductscience.org/library/papers/29653857PubMed

See all 113 references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42,897,128Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42897128PubMed
42,317,522Advances in oncolytic virus delivery strategies and challenges in clinical translation.Mater Today Bio2026https://conductscience.org/library/papers/42317522PubMed
41,618,502Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/41618502PubMed
41,294,689Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends.Curr Oncol2025https://conductscience.org/library/papers/41294689PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40539780

GET https://conductscience.org/api/papers/v1/40539780/references?page=2